Telehealth-Based Chronic Disease Management for Type 2 Diabetes
ConditionType 2 DM
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorZeng Lin, Ph. D.
About this trial
This study will be conducted from enrollment until the end of the six-month follow-up period.
This study aims to assess the impact of the Internet hospital online + offline integrated chronic disease management model on patients with type 2 diabetes mellitus. It will also evaluate the economic impact of the model and identify the characteristics of the appropriate population for the model. Finally, it will develop a toolkit to help manage chronic diseases.
The study will include 1,636 patients with type 2 diabetes who did not reach the standard of control target of glucose, blood pressure or LDL at the endocrine outpatient clinic and inpatient wards of the Third Hospital of Peking University. We will collect information from participants before the study starts. And the patients will be followed up for 6 months from enrollment. The study management mode included online and offline integrated management in the Internet hospital, and routine offline management mode. After completing the enrollment and assessment, we will arrange outpatient follow-up and management according to the current status, doctor's requirements, and study subjects' needs.
Eligibility criteria
Qualifiers
18-70 years old;
Confirmed diagnosis of type 2 diabetes mellitus;
Ability to use smartphones to participate in online diagnosis and treatment;
Ability of the patient or relatives to assist the patient in self-monitoring of blood glucose;
Disqualifiers
Mental illness, cognitive dysfunction;
Other diseases and complex conditions (untreated tumors, heart disease within 3 months);
Acute complications of diabetes, severe hyperglycemia, fasting glucose greater than 16.9 mmol / L, random glucose greater than 20 mmol / L. Diabetic ketoacidosis and hypoglycemic coma that are not suitable for online management of diabetes emergencies;
Patients with severe chronic complications of diabetes in critical condition (blindness, vision deterioration, new onset of ASCVD symptoms);
Trial design
Treatments tested in this trial
- Not listed
Trial groups
1,636 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Zeng Lin, Ph. D.
Lead sponsor
Peking University Third Hospital
Sponsor institution
Source ClinicalTrials.gov